

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Alzheimer's disease (AD)	β -amyloid (A β)	A series of ^{18}F -labeled 2-(4'-fluorophenyl)-1,3-benzothiazoles with a longer half-life than existing A β -labeling compounds may have potential as PET imaging agents for early diagnosis of AD. In human AD postmortem brain homogenates, three of the compounds had low K_i values and high binding affinities for A β plaques. Studies in mice and rats showed that initial brain uptake of the compounds was high and clearance was fast. Next steps include evaluating the labeled tracers in AD patients.	Patented; licensing status unknown	Serdons, K. <i>et al. J. Med. Chem.</i> ; published online Feb. 13, 2009; doi:10.1021/jm8013376 Contact: Kim Serdons, Catholic University Leuven, Leuven, Belgium e-mail: kim.serdons@pharm.kuleuven.be
<p>SciBX 2(8); doi:10.1038/scibx.2009.326 Published online Feb. 26, 2009</p>				